Thursday, April 08, 2021 12:12:52 AM
LumiraDx partnered with Chembio Diagnostics to develop a COVID-19 diagnostic for its microfluidic point-of-care testing system in March 2020.
On April 7, 2021, LuminarDX announced that it will combine with CA Healthcare Acquisition Corp, in a deal that values LumiraDx’s equity at $5 billion
https://www.businesswire.com/news/home/20210406006194/en/LumiraDx-a-Next-Generation-Point-of-Care-Diagnostics-Testing-Company-to-List-on-Nasdaq-via-Merger-with-CA-Healthcare-Acquisition-Corp
Recent CEMI News
- Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer • PR Newswire (US) • 10/17/2023 09:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM